Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Research analysts at Wedbush raised their FY2023 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report issued on Tuesday, November 7th. Wedbush analyst L. Chico now expects that the company will earn ($2.37) per share for the year, up from their previous forecast of ($2.44). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.58) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q4 2023 earnings at ($0.59) EPS, Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.56) EPS, Q3 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.54) EPS, FY2024 earnings at ($2.21) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($2.96) EPS and FY2027 earnings at ($1.48) EPS.
STOK has been the topic of a number of other research reports. Credit Suisse Group restated an “outperform” rating and set a $23.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 8th. Cantor Fitzgerald decreased their target price on Stoke Therapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 8th. TD Cowen downgraded Stoke Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 25th. Needham & Company LLC reduced their price objective on shares of Stoke Therapeutics from $25.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.
Stoke Therapeutics Price Performance
Shares of NASDAQ:STOK opened at $4.26 on Friday. The firm’s 50 day simple moving average is $4.24 and its two-hundred day simple moving average is $7.68. The company has a market capitalization of $190.21 million, a P/E ratio of -1.76 and a beta of 0.45. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $14.00.
Institutional Trading of Stoke Therapeutics
Several hedge funds have recently made changes to their positions in STOK. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $25,000. Point72 Hong Kong Ltd bought a new stake in Stoke Therapeutics in the first quarter worth $27,000. Great West Life Assurance Co. Can boosted its stake in Stoke Therapeutics by 46.7% during the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after buying an additional 1,078 shares during the period. Dorsey & Whitney Trust CO LLC bought a new position in Stoke Therapeutics during the third quarter valued at $43,000. Finally, UBS Group AG purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at $47,000.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
- Five stocks we like better than Stoke Therapeutics
- Investing in large cap stocks: Diving into big caps
- Data giants MongoDB and Snowflake just got upgraded
- How to Effectively Use the MarketBeat Ratings Screener
- Plug Power at tipping point; it’s make or break time for hydrogen
- How to Use the MarketBeat Stock Screener
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.